Andrew Saik
CIK 1616284 · Chief Financial Officer · last filed 2026-05-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.58M
Companies
8
Total Filings
36
Lifetime Open-Market Net
-$156.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARVN | Chief Financial Officer | 193,128 | $7.58 | $1.46M | -$215.1K | 7 | 2026-05-13 |
| MIST | Director | — | $1.27 | — | $0 | 3 | 2025-06-12 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | EVP & Chief Financial Officer | 68,265 | $19.00 | $1.30M | $0 | 10 | 2023-09-25 |
| VYNE | Chief Financial Officer | 116,468 | $0.65 | $75.5K | $58.5K | 4 | 2021-06-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Financial Officer | 300,000 | — | — | $0 | 2 | 2020-05-08 |
| PDSB | Chief Financial Officer | 42,549 | $1.05 | $44.7K | $0 | 3 | 2020-02-19 |
| EDGE | Chief Financial Officer | — | $49.07 | — | $0 | 4 | 2018-08-15 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | CFO | 0 | — | — | $0 | 2 | 2015-01-30 |
Recent Filings · Page 3 of 4
36 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-22 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +52,156 | $0 | EDGAR |
| 2021-06-02 | VYNE | Grant (A) | +3,017 | $10.1K | EDGAR |
| 2021-04-02 | VYNE | Tax (F) | −762 | -$5.2K | EDGAR |
| 2021-02-24 | VYNE | Grant (A) | +29,213 | $0 | EDGAR |
| 2020-09-08 | VYNE | Buy (P) | +40,000 | $58.5K | EDGAR |
| 2020-05-08 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +250,000 | $0 | EDGAR |
| 2020-03-24 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
| 2020-02-19 | PDSB | Grant (A) | +38,400 | $49.9K | EDGAR |
| 2019-06-07 | PDSB | Grant (A) | — | $0 | EDGAR |
| 2019-03-18 | PDSB | Exer (M) | +82,999 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.